Lv1
60 积分 2023-08-07 加入
Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas
6天前
已完结
A paradigm of cancer immunotherapy based on 2-[18F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect
10个月前
已完结
Natural killer cell therapies
1年前
已完结
Advances in Radionuclide-Labeled Biological Carriers for Tumor Imaging and Treatment
1年前
已完结
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST
1年前
已完结
皖公网安备34019202002308
